Form 4: OptiNose Chief Commercial Officer Disposes of Shares and Options Following Merger with Paratek Pharmaceuticals

Paul Spence Jr., Chief Commercial Officer of OptiNose, Inc., reports the disposal of common stock and stock options due to the merger with Paratek Pharmaceuticals, Inc.

Summary

• Paul Spence Jr., Chief Commercial Officer of OptiNose, Inc., filed a Form 4 detailing changes in beneficial ownership.
• The filing is triggered by the merger between OptiNose and Paratek Pharmaceuticals, Inc., which became effective on May 21, 2025.
• As a result of the merger, Spence's common stock and stock options were affected.
• Each share of common stock was converted into the right to receive $9.00 in cash and one contingent value right (CVR).
• Vested restricted stock units (RSUs) were canceled, with holders receiving cash and CVRs.
• Unvested RSUs were canceled, with holders contingently entitled to cash and CVRs upon vesting.
• Stock options were converted into the right to receive cash equal to the excess of $9.00 over the exercise price, with certain options canceled for no consideration or converted into CVRs.
• Spence disposed of 102,813 shares of common stock.
• Spence disposed of stock options to buy 8,525 shares at $5.77, 33,333 shares at $26.25 and 8,422 shares at $27.30.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to a merger. It's neutral in tone and simply reports the changes in beneficial ownership. The sentiment is moderately positive as the merger provides shareholders with cash and potential future value through CVRs.

Future Outlook

The document outlines the financial implications for Paul Spence Jr. following the merger, specifically regarding the conversion and cancellation of his stock and stock options. The future value of the CVRs is contingent on the achievement of specified milestones.

Industry Context

This announcement reflects a common scenario following a merger or acquisition, where executives' stock and option holdings are converted or cashed out according to the terms of the merger agreement. This is a standard part of the M&A process.

Comparison to Industry Standards

• Merger agreements commonly include provisions for the treatment of outstanding equity awards, such as stock options and restricted stock units.
• The conversion of common stock into cash and contingent value rights is a structure used in acquisitions to provide shareholders with upfront value and potential future payouts based on the achievement of milestones.
• The cancellation of stock options with exercise prices above the acquisition price is a standard practice in M&A transactions.
• Similar to the OptiNose deal, many biotech acquisitions involve CVRs tied to regulatory approvals or sales targets, offering shareholders additional upside potential.

Stakeholder Impact

• Shareholders received $9.00 in cash and one CVR per share.
• Employees with RSUs received cash and CVRs, with unvested RSUs subject to continued vesting terms.
• Option holders received cash for options with exercise prices below $9.00, while some options were converted to CVRs or canceled.

Key Dates

Keywords

Merger, OptiNose, Paratek Pharmaceuticals, Form 4, Beneficial Ownership, Stock Options, Common Stock, Contingent Value Right, CVR, Restricted Stock Units, RSU, Spence, Chief Commercial Officer